No difference in retinal fluorescence after oral curcumin intake in amyloid-proven AD cases compared to controls.

ABSTRACT:

Introduction

Previous work has showed the in vivo presence of retinal amyloid in Alzheimer's disease (AD) patients using curcumin. We aimed to replicate these findings in an amyloid biomarker-confirmed cohort.

Methods

Twenty-six patients with AD (age 66 [+9], Mini-Mental Status Examination [MMSE] ≥17) and 14 controls (age 71 [+12]) used one of three curcumin formulations: Longvida, Theracurmin, and Novasol. Plasma levels were determined and pre- and post-curcumin retinal fluorescence scans were assessed visually in all cases and quantitatively assessed in a subset.

Results

Visual assessment showed no difference between AD patients and controls for pre- and post-curcumin images. This was confirmed by quantitative analyses on a subset. Mean conjugated plasma curcumin le

SUBMITTER: den Haan J 

PROVIDER: S-EPMC9376971 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature